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Abstract
Background: Immunologically distinct forms of Shiga toxin (Stx1 and Stx2) display different potencies and disease
outcomes, likely due to differences in host cell binding. The glycolipid globotriaosylceramide (Gb3) has been reported to be
the receptor for both toxins. While there is considerable data to suggest that Gb3 can bind Stx1, binding of Stx2 to Gb3 is
variable.
Methodology: We used isothermal titration calorimetry (ITC) and enzyme-linked immunosorbent assay (ELISA) to examine
binding of Stx1 and Stx2 to various glycans, glycosphingolipids, and glycosphingolipid mixtures in the presence or absence
of membrane components, phosphatidylcholine, and cholesterol. We have also assessed the ability of glycolipids mixtures
to neutralize Stx-mediated inhibition of protein synthesis in Vero kidney cells.
Results: By ITC, Stx1 bound both Pk (the trisaccharide on Gb3) and P (the tetrasaccharide on globotetraosylceramide, Gb4),
while Stx2 did not bind to either glycan. Binding to neutral glycolipids individually and in combination was assessed by
ELISA. Stx1 bound to glycolipids Gb3 and Gb4, and Gb3 mixed with other neural glycolipids, while Stx2 only bound to Gb3
mixtures. In the presence of phosphatidylcholine and cholesterol, both Stx1 and Stx2 bound well to Gb3 or Gb4 alone or
mixed with other neutral glycolipids. Pre-incubation with Gb3 in the presence of phosphatidylcholine and cholesterol
neutralized Stx1, but not Stx2 toxicity to Vero cells.
Conclusions: Stx1 binds primarily to the glycan, but Stx2 binding is influenced by residues in the ceramide portion of Gb3
and the lipid environment. Nanomolar affinities were obtained for both toxins to immobilized glycolipids mixtures, while
the effective dose for 50% inhibition (ED50) of protein synthesis was about 10
211 M. The failure of preincubation with Gb3
to protect cells from Stx2 suggests that in addition to glycolipid expression, other cellular components contribute to toxin
potency.
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Introduction
Escherichia coli O157:H7 is the most common serotype of Shiga
toxin-producing E. coli isolated from patients in the United States.
It is estimated to cause 110,000 cases, mostly among children and
the elderly, and 3,200 hospitalizations annually in the United
States, costing approximately 400 million dollars [1,2]. This
pathogen causes food-borne disease with symptom severity that
varies from mild diarrhea to hemorrhagic colitis, and potentially to
life-threatening Hemolytic Uremic Syndrome (HUS) [3]. Shiga
toxin (Stx), the most important virulence factor of E. coli O157:H7,
is responsible for the life-threatening complications following
infection. Stx is an AB5 toxin consisting of a single A subunit
associated with a pentamer of identical B subunits. This pentamer
binds to the glycosphingolipid globotriaosylceramide (Gb3) in host
cell membranes [4,5,6,7] and delivers the A subunit into the
cytoplasm. In the cytoplasm, the enzymatically active A subunit
inhibits protein synthesis by cleaving an adenine nucleotide from
28S RNA within the 60S ribosomal subunit, preventing tRNA
binding and protein synthesis [8,9].
There are two immunologically distinct forms of Stx: Stx1 and
Stx2. They share 56.8% amino acid sequence identity [10,11]. In
epidemiological studies, Stx2 is more often associated with severe
disease outcome and development of HUS than Stx1 [3]. In animal
models, Stx2 is 100- to 400-fold more potent than Stx1 [12,13,14].
Differences in host cell receptor binding between Stx1 and Stx2
appear to mediate the differences in potency in vivo and in vitro
[13,15,16,17,18]. Shimizu et al. reported that a chimeric toxin with
the Stx2A subunit associated with the Stx1B-pentamer was 2-fold
more toxic to mice than wild type Stx1 and 50-fold less potent than
wild type Stx2, suggesting that the A subunit does not significantly
contribute to potency in vivo, while the B-pentamer play a more
significant role [6]. These data suggest that Stx potency might be
due to a differential targeting or affinity in binding to host cell
receptors. When Stx1 or Stx2 is administered to mice, Stx1 stays
predominantly the lungs without causing pathology while Stx2
mainly targets the kidneys [13,19]. It has been suggested that Stx1
might bind to Gb3 variants in the lungs, preventing it from reaching
more susceptible organs such as the kidneys, whereas Stx2 binds
preferentially to Gb3 variants in kidney tissue.
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present in Gb3 occurs primarily through hydrogen bonds between
the hydroxyl groups on the sugars. High affinity is achieved
through avidity, by engaging multiple binding sites on the toxin.
The Stx1 B-pentamer has 3 Pk trisaccharide binding sites per
subunit, or 15 sites total per holotoxin [20]. In contrast, the
binding sites for Stx2 are less well defined, but the binding
interactions have been modeled [21,22]. Interestingly, binding
studies using receptor mimics show that Stx1 binds with higher
affinity to the Pk trisaccharide than Stx2 [15,23,24,25,26].
Published data demonstrate different and selective binding
preferences of Stx1 and Stx2 to synthetic glycans. Stx1 shows a
preference for binding native Pk while Stx2 binds better to an N-
acetylated analogue of Pk (NAc-Pk) [16,24,27]. Native Pk
trisaccharide is found on glycolipid Gb3, while NAc-Pk is found
on proteins, but no glycolipids with NAc-Pk are known to exist in
nature.
Native Gb3 is found on the lipid rafts (detergent-insoluble
glycolipid-enriched domains) in host cell membranes. Lipids rafts
are composed of (glyco)sphingolipids, glycerophospholipids, and
cholesterol. Stx2 variants, such as porcine edema disease toxin
(Stx2e), have been reported to bind to glycosphingolipid
globotetraosylceramide (Gb4), which contains an additional
residue, GalNAc, attached to the Pk of Gb3 [28,29]. In a recent
report, Gb3 was found to be present in low quantities in colonic
epithelial cells in vivo; whereas Gb4 was found abundantly [30].
Low affinity binding of Stx1 to Gb4 has been reported [30],
suggesting that Stx1 could bind to these glycolipids in host cells
membranes. However, the true functional receptor of Stx remains
unknown. It is not clear if Gb3 is the main factor mediating Stx
binding to host cells, and in vitro binding affinities do not correlate
with cellular or in vivo toxicity. Previous data shows that Stx
affinity for Gb3 is in the nanomolar range while cellular and in
vivo toxicity are in the picomolar range, suggesting other factor
might also play a role of Stx toxicity in vivo and at cellular level
[12,15,23].
Recently, it has been reported that lectin binding was enhanced
in the presence of glycolipid mixtures as compared to the binding
to single glycolipids [31]. Considering that glycolipids are naturally
found in the cell membrane in mixtures and in combination with
phospholipids and cholesterol [32,33], Stx binding in vivo might
involve more than one glycolipid, and the presence of cholesterol
and phospholipids.
The objective of this study was to gain insight into the receptor
preferences for Stx1 and Stx2. We examined binding of Stx1 and
Stx2 to various glycans, glycolipids and glycolipid mixtures by ITC
or ELISA in the presence or absence of phosphatidylcholine (PC)
and cholesterol (Ch). The findings of this study have clarified the
differences in binding of Stx1 and Stx2.
Results
Characterization of individual glycan binding sites by ITC
While the glycolipid Gb3 is commonly reported to be the
receptor for both Stx1 and Stx2, the two toxins appear to have
different receptor preferences. We used ITC to examine binding of
Stx1 and Stx2 to the Pk-trisaccharide expressed on Gb3. To avoid
complications due to A-subunit interactions, binding studies were
performed with purified B-pentamer. Stx1B bound to Gb3 with a
Kd of about 4 mM (Figure 1A), which is in good agreement with
previously published studies using ITC [34] and mass spectrom-
etry [35]. In contrast, no binding of Stx2B to Pk was detected
under the experimental conditions tested (Figure 1B).
In previous reports, Stx1 and Stx2 binding to Gb4 was observed
[23,29,36,37,38] and recently Stx1 has been reported to bind to
Gb4 [30]. However, nothing is known about the number or
affinity of single sites for Gb4. Stx1B bound to the P
tetrasaccharide expressed on Gb4 with a Kd of 12 mM
(Figure 1C), with about 3-fold lower affinity compared to Gb3.
These results demonstrate that Stx1 might recognize Gb4 as
receptor. Like Pk, no binding of Stx2B to P-tetrasaccharide was
observed (Figure 1D), which suggested that the Kd of Stx2B for
both glycans is much greater than 12 mM.
Stx binding to synthetic glycans
To identify other possible glycan receptors, Stx1 and Stx2
toxoids were assayed by ELISA for binding to 465 different
glycans by the Consortium for Functional Glycomics. To avoid
exposure to the high concentrations of toxin typically used in
binding studies, these studies were performed with genetically
inactivated toxin. The two amino acid changes (Tyr77Ser and
Glu167Gln) abolish the enzymatic activity of the A-subunit, but do
not affect binding mediated by the B-pentamer [39,40].
No significant binding was detected for Stx2 at 0.64 mM (data
not shown). Binding to Stx1 was detected. The top three hits for
Figure 1. Binding of Stx1 and Stx2 to purified Pk trisaccharide
and P tetrasaccharide by ITC. Glycans (50 mM) were titrated into a
microcalorimeter cell containing 238–300 mM of Stx B-subunits. Stx
binding interaction with Pk (A, B) and P tetrasaccharide (C, D). Both Stx1
B-subunits (A–C) and Stx2 B-subunits (B–D) raw heat signals (top) and
integrated data from titrations (bottom) are shown.
doi:10.1371/journal.pone.0030368.g001
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trisaccharide, with Gala1-4Gal as the terminal sugars; however
they differed from Pk at the third sugar, which was GlcNAc
instead of Glc (Figure 2). Interestingly, Stx1 did not display
significant binding to glycan 121, containing the native Pk antigen.
However, consistent with the above results, 7-fold more binding of
Stx1 was observed to glycan 119 (the 6
th best hit) which only
differed from glycan 121 by the presence of N-acetylation at the
third residue, suggesting GlcNAc may be the preferred residue.
However, in nature, this glycan (Gala1-4Galb1-4GlcNAc) occurs
in mammalian glycosylated proteins, but not on glycolipids.
Additionally, the linker used to attach the glycans to the array
surface matrix can influence toxin binding [24,41,42]. Glycan 120
and glycan 119 share the identical glycan trisaccharide, but are
attached with different linkers. A change from the Sp0 linker
(-CH2CH2NH2) to the Sp8 linker (-CH2CH2CH2NH2) increased
Stx1 binding by 2-fold.
Stx binding to native Gb3 glycolipid
The failure of the glycan array to reveal binding of Stx1 to
native Pk, and the inability to detect any ligands for Stx2 led us to
examine binding to native glycolipids. In initial experiments,
binding at several concentrations of Stx was assessed using pure
Gb3 immobilized on hydrophobic microtiter ELISA plates with
incubations at 4uC. The apparent dissociation constant (Kd)o f
Stx1 binding to Gb3 was determined to be 4.2 nM (Figure 3)
which is 10-fold lower than the 46 nM value reported with radio-
labeled Stx1 and 48-fold lower than the 222 nM value reported
with Surface Plasmon Resonance (SPR) [15,23]. There are several
explanations for the different apparent Kd values obtained in
different studies. ELISA has been shown to be more sensitive than
SPR [16,43], possibly because the longer incubation periods in the
static ELISA allows the toxin to achieve optimal interacting
conformation compared to the dynamic flow conditions of SPR
[42]. Additionally, we incubated the plates at 4uC, while the SPR
studies were done at room temperature.
In contrast a Kd for Stx2 binding to Gb3 was not determined
due to the high concentration of toxin (above 1 mM) needed to
reach saturated binding under these conditions (Figure 3). Previous
studies reported low affinity binding of Stx2 to Gb3 using radio-
labeled Stx2 (Kd=370 nM) and SPR (Kd=1040 nM) [15,23].
Stx binding to glycolipid complexes
Rinaldi et al. (2009) suggested that mixed glycolipid complexes
may support better binding than pure glycolipids. Neutral
glycolipids of the glucosylceramide family are synthesized by
sequential addition of sugars to the ceramide core, culminating
with the tetrasaccharide form, Gb4 (Table 1). The glucosylcer-
amides display a broad cellular distribution. In contrast, the
glycolipid galactosyl ceramide (Gal-Cer), which is synthesized by a
different pathway, is found primarily on neuronal tissue [44,45].
Since selective binding to Stx2 to NAc-Pk is reported, we also
evaluated binding of Stx to asialo GM1 (aGM1) and asialo GM2
(aGM2) gangliosides [16,24]. The glycan portion of aGM1
(GalNAcb1-4Galb1-4Glc) is similar to NAc-Pk except for the
b1–4 instead of a1–4 linkage of the terminal GalNAc residue;
aGM2 is a derivative of aGM1 with an additional Gal residue
added with a b1–3 linkage.
We examined binding of Stx1 and Stx2 to the neutral
glycolipids, alone or in combination (Figure 4A). Stx1 (10 nM)
bound to Gb3 and Gb4, but not to Glc-Cer, Lac-Cer, Gal-Cer,
aGM1 or aGM2 (Figure 4A, white bars). Stx1 also bound to 1:1
mixtures of Gb3 and the other glycolipids, and some mixtures of
Gb4. In contrast, strong binding of Stx2 was only observed for
Gb3 mixed with Glc-Cer, Lac-Cer or Gal-Cer (Figure 4A, black
bars).
In mammalian cells, glycolipids in lipid rafts are arrayed in fluid
membranes containing cholesterol (Ch) and phosphatidylcholine
(PC). We also examined Stx binding to glycolipid mixtures in the
presence of these other membrane components (Figure 4B).
Individual glycolipids Glc-Cer, Lac-Cer, Gal-Cer, aGM1 and
aGM2 failed to support binding of either Stx1 or Stx2 even in the
presence of Ch and PC (Figure 4B). However, the presence of Ch
Figure 2. Glycan array results for Stx1. Binding of Stx1 (2.84 mM)
toxoid to the CONSORTIUM FOR FUNCTIONAL GLYCOMICS MAMMALIAN Array Version
4.1 with 465 different natural and synthetic mammalian glycans was
assessed by ELISA. Displayed are the top three hits for Stx1 (glycans 331,
402, and 120). For comparison, also displayed is native Pk (glycan 121),
glycan 119 which is attached using the same linker as native Pk, and
glycan 120, which is attached with a different linker from 119. The
symbolic representation of the compounds follows the CFG standards:
galactose (Gal, white circle), glucose, (Glc, black circle), N-acetyl-
glucosamine (GlcNAc, black square), mannose (Man, gray circle). X
corresponds to b1-4GlcNAcb1-4GlcNAcb-LVANKT. Spacers used to
couple the glycans to the array surface matrix: Sp0, -CH2CH2NH2; Sp8,
-CH2CH2CH2NH2; LVANKT, peptide (Leucine, L; valine, V; alanine, A;
asparagine, N; lysine, K; threonine, T). Relative fluorescence units (RFU)
signal is the mean of four independent experiments and error bars
indicate Standard Deviation (SD).
doi:10.1371/journal.pone.0030368.g002
Figure 3. Stx binding to pure Gb3. Stx1 (black squares, &) and Stx2
(black circles,N) toxoid binding affinity to Gb3 alone was assessed by
ELISA at 4uC. Stx1 binding as fitted to a one-site specific binding model
with Hill coefficients. Symbols represent experimental data, while lines
represent the fitted model for that data analyzed with Prism5
(GraphPad software, La Jolla, CA). Values for Stx2 were not determined
due to poor binding. The RFU signal is the mean of three independent
experiments and error bars indicate SD.
doi:10.1371/journal.pone.0030368.g003
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Gb3 and Gb4, and both toxins bound to a broader array of glycan
mixtures. These initial studies were performed at 4uC. Since
membrane fluidity is much greater at physiological temperatures,
we repeated these binding studies at 37uC. Incubation at 37uC
only resulted in significantly increased binding to Gb3 and Gb4
reflected in higher RFU values (data not shown).
The apparent Kd of Stx1 and Stx2 for Gb3 and Gb4 in the
presence of Ch+PC was assessed at 37uC (Figure 5). The apparent
Kd of Stx1 for Gb3 in the presence of Ch+PC was 6.4 nM, which
is very similar 4.2 nM, the apparent Kd of Stx1 for Gb3 at 4uC
without Ch+PC (Figure 3). However, the shape of the binding
curves was very different, a reflection of the very different hill
coefficients (nH), 1.4 for pure Gb3 at 4uC (Figure 3) versus
nH=0.38 for binding to Gb3 with Ch and PC at 37uC (Figure 5A).
Since Stx1 has multiple binding sites for Pk, the Hill coefficient of
less than 1 seen for Gb3 in the presence of PC and Ch suggests
different classes of apparent affinity of the Stx1 toxoid for binding
to the plate. This reflects differing levels of avidity rather than
differences in individual sites on the Stx1 B-pentamer, likely due to
microheterogeneity in the lipid makeup at the plate surface. The
avidity of Stx1 for Gb4 was nearly identical to Gb3 alone, with an
apparent Kd of 3.9 nM compared to 6.4 nM (Figure 5A), but Gb4
supported less binding than Gb3. Binding of Stx1 to Gb3/Gb4
mixture displayed an apparent Kd (6.2 nM) very similar to that
obtained with either glycolipid alone. Interestingly, in the presence
of Ch and PC, Stx2 binding to Gb3, Gb4 or mixtures was very
similar to Stx1, both in global affinity (Kd of 6.4 nM, 14 nM, and
3.2 nM, respectively) and displaying Hill coefficients of less than 1.
The differences in Bmax for Gb4 compared to Gb3 or Gb3/Gb4
for both toxins is significant. This suggests that the number of
individual sites on both Stx B-pentamers that can bind Gb4 are
presumably lower than the number of sites able to bind Gb3;
resulting in a less stringent binding of the B-pentamer to Gb3
compared to Gb4. In support of this hypothesis, similar results
(glycans with identical apparent Kd but very different Bmax values)
were observed for pertussis toxin, an AB5 toxin with non-identical
B-subunits known to possess structurally and functionally hetero-
geneous glycan binding sites [41].
Contribution of the ceramide to Stx binding
To determine if the sphingosine residues in the ceramide
portion of Gb3 molecule played a role in binding to Stx2, we
assessed binding to variants of Gb3 with or without the a-
hydroxylated fatty acid (OH FA) in the ceramide (Figure 6).
Binding of these variants was compared to the preparation that
contains both variants, hydroxyl and nonhydroxyl fatty acid
chains, used in Figures 3, 4, 5. Stx1 displayed similar binding to
Gb3 regardless of presence of the ceramide hydroxyl or the
presence of Ch and PC (Figure 6A). In the absence of PC and Ch,
Table 1. Glycolipids used in this study.
Name (abbreviation, product number) Structure Empirical Formula
Glucosyl ceramide (Glc-Cer, 1521) Glc-Ceramide C48H93NO8
Lactosyl ceramide (Lac-Cer, 1507) Galb1-4Glc-Ceramide C53H101NO13
Globotriaosyl ceramide, Ceramide trihexoside (Gb3, 1067) Gala1-4Galb1-4Glc-Ceramide C60H113NO18
Globotetraosyl ceramide (Gb4, 1068) GalNAcb1-3Gala1-4Galb1-4Glc-Ceramide C68H126N2O23
Gb3 with non-hydroxy fatty acid side chain (Gb3 –OH, 1513) Gala1-4Galb1-4Glc-Ceramide C54H101NO18
Gb3 with hydroxy fatty acid side chain (Gb3 +OH, 1514) Gala1-4Galb1-4Glc-Ceramide C54H101NO19
Lyso-globotriaosylsphingosine (Lyso-Gb3, 1520) Gala1-4Galb1-4Glc-Ceramide C36H67NO17
Galactosyl ceramide (Gal-Cer, 1050) Gal-Ceramide C48H93N08
Asialo GM2 gangliosides (aGM2, 1512) GalNAcb1-4Galb1-4Glc-Ceramide C56H104N2018
Asialo GM1 gangliosides (aGM1, 1064) Galb1-3GalNAcb1-4Galb1-4Glc-Ceramide C62H114N2023
doi:10.1371/journal.pone.0030368.t001
Figure 4. Binding of Stx1 and Stx2 to purified glycolipids and
mixtures. Stx binding was assessed by ELISA at 10 nM for both Stx1
(white columns) and Stx2 (black columns) at 4uC. The RFU signal is the
mean of three independent experiments and error bars indicate SD.
Since different antibodies were used to detect Stx1 and Stx2, two axes
are shown. (A) Binding of Stx1 and Stx2 to purified glycolipids
and mixtures in absence of Ch and PC. Mixtures of glycolipids were
prepared in methanol at a ratio of 1:1 and added at 200 ng of total
glycolipid per well. (B) Binding of Stx1 and Stx2 to purified
glycolipids and mixtures in the presence of Ch and PC. Mixtures
were prepared in methanol at a ratio of glycolipid 1, glycolipid 2,
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hydroxyl was present, and in the presence of PC and Ch bound
equally to Gb3 expressing either form of ceramide (Figure 6B).
These results demonstrate that the hydroxyl residue in the fatty
chain of the sphingosine part of Gb3 does not play a significant
role in binding to either Stx1 or Stx2, and agree with previous
reports that the OH FA variants of Gb3 display similar binding
affinities for both Stx1 and Stx2 [36].
To investigate further the role of the ceramide in Stx binding,
we evaluated binding to deacylated Gb3 (Lyso-Gb3). Lyso-Gb3
lacks a carbony group and one fatty acid chain (acyl group) in the
sphingosine of Gb3 (Figure 7). Stx1 displayed about a third as
much binding to Lyso-Gb3 in the presence of Ch and PC
(Figure 7A). Stx2 did not bind to Lyso-Gb3 in the presence or
absence of Ch and PC (Figure 7B). These results demonstrate that
either the presence of the ketone group or the acyl group in Gb3 is
essential for binding to Stx2 at low concentrations of toxin. ELISA
probing coated wells with an anti-Gb3 antibody suggest that about
2.8 times more Gb3 than lyso-Gb3 binds to the hydrophobic well
in the presence of +PC+Ch; therefore, reduced binding of Stx1 for
lyso-Gb3 is likely due to less ligand, and not a reflection of reduced
binding affinity of Stx1 to lyso-Gb3 (data not shown). While
previous studies reported that Stx1 and Stx2 are able to bind to
Lyso-Gb3 by thin layer chromatography [46], receptor binding
ELISA [47,48,49], or radio-labeled Stx [50], these studies did not
compare binding of Lyso-Gb3 to native Gb3. Our results show
weak binding of Stx to Lyso Gb3 when compared to native Gb3,
which agrees with previous observations [46,50].
Contribution of cholesterol to Stx binding
To determine whether Ch or PC is important to Stx2 binding,
we assessed the binding in the absence of either Ch or PC
(Figure 8). The absence of cholesterol caused a statistically
significant decrease in the binding of Stx1 and Stx2. The presence
of cholesterol alone caused a statistically significant increase in the
binding of Stx2 to Gb3. These results are consistent with published
data by other groups that demonstrate the presence of cholesterol
modulates binding to glycosphingolipids [37,51,52,53,54], and PC
does not appear to be required for enhanced binding.
Yahi et al. reported that cholesterol forms hydrogen bonds with
glycosphingolipids by the interaction of the OH of cholesterol
(donor group), the NH of sphingosine (acceptor group), and the
oxygen atom of the glycosidic bond [acceptor group [52]]. These
interactions change the glycolipid conformation and alter
glycolipid interactions with proteins. For example, cholesterol
has been reported to alter the ability of pathogens such as HIV to
interact with the cell [55]. To investigate the role of the OH of
cholesterol, we evaluated the binding of Stx1 and Stx2 to Gb3 in
Figure 5. Stx binding to Gb3, Gb4 and Gb3/Gb4 mixture in the
presence of cholesterol and phosphatidylcholine. Stx1 (A) and
Stx2 (B) toxoid binding was assessed by ELISA at 37uC. As negative
controls, toxin was incubated in methanol, PC, Ch, or PC+Ch coated
wells. In all experiments, background RFU values obtained in methanol
were subtracted from each value. Binding curves were fitted to a one-
site specific binding model with Hill coefficients. Symbols represent
experimental data, while lines represent the fitted model for that data
analyzed with Prism5 (GraphPad software, La Jolla, CA). The RFU signal
is the mean of three independent experiments and error bars indicate
SD.
doi:10.1371/journal.pone.0030368.g005
Figure 6. Stx binding to Gb3 analogs. Stx binding was assessed by
ELISA at 10 nM for both Stx1 (A) and Stx2 (B)a t3 7 uC. Gb3 2OH FA,
with non-hydroxy Fatty Acid chain; +OH FA with hydroxy Fatty Acid
chain. If not specified Gb3 is a standardized mixture that contains both
variants with hydroxyl and nonhydroxyl fatty acid chains (Matreya Inc.).
As negative controls, toxin was incubated in methanol, PC, Ch, or
PC+Ch coated wells. In all experiments, RFU values obtained in
methanol were subtracted from each value in order to define a base
level. The RFU signal is the mean of three independent experiments and
error bars indicate SD.
doi:10.1371/journal.pone.0030368.g006
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analog lacks the OH group at Carbon 3 and has an alkane bond in
Carbon 5 (Figure 9C). Stx1 bound equally well in the presence of
Ch or 5aCh and PC (Figure 9A). In contrast, 5aCh failed to
support binding of Stx2 in the presence of PC (Figure 9B). These
results demonstrated that the presence of the OH group in
cholesterol plays a role in modulating the binding of Stx2 but not
Stx1.
Stx cellular toxicity in vero protection assay
Little binding of Stx to glycolipids was observed at sub-
nanomolar levels (Figures 3 and 5). However, cellular toxicity has
been reported to occur at much lower concentrations [12]. Stx
causes toxicity by cleaving the 28S rRNA of target cells, thereby
inhibiting protein synthesis [8,9]. We assessed Stx-mediated
inhibition of protein synthesis using Vero monkey kidney cells
engineered to express a destabilized form of luciferase, Luc2P.
Luc2P is targeted to the proteosome for degradation. Since it
cannot accumulate in the cell, the amount of luciferase activity is
proportional to the current rate of protein synthesis.
To assess the ability of glycolipids to neutralize cellular toxicity,
serial dilutions of Stx were incubated in glycolipid-coated
microtiter plates at 37uC for 1 hour, essentially as described in
Figure 5. The supernatant containing unbound toxin was
transferred to plates containing the Luc2P Vero cells. Protein
synthesis inhibition was assessed after 4 hours of incubation with
the toxin.
In this assay, the ED50 for untreated Stx1 was 0.3610
211,a n d
the ED50 for untreated Stx2 was 5610
211. Pre-incubation of Stx1
in wells treated with methanol (Figure 10A, open inverted
triangles) or PC+Ch (Figure 10A, open triangles) did not result in
decreased toxicity, as seen by no change in ED50 compared to the
untreated control (Figure 10A, insert). Pre-incubation with
Gb4+PC+Ch (Figure 10A, open squares) was not able to protect
Vero cells. However, pre-incubation of Stx1 with Gb3+PC+Ch
(Figure 10A, open circles) resulted in significantly reduced
toxicity, with about a 10-fold increase in the ED50 compared to
untreated Stx1 (Figure 10A, insert). In contrast, Stx2 was not
neutralized by any of the treatments since there were no
significant differences in the ED50 values for treated or untreated
toxin (Figure 10B: insert).
Discussion
The present study provides insights into the difference in
receptor recognition by Stx1 and Stx2. While Stx1 binds with
similar affinity to the Pk glycan and the Gb3 glycolipid (Figure 5),
Stx2 does not recognize Pk alone, but can bind in the context of
Gb3 glycolipid and other molecules (Figures 4, 5). We found that
Stx1 can also bind to the P tetrasaccharide (Figure 1) and the Gb4
glycolipid (Figure 4, 5), which has not been reported previously.
While Stx2 did not bind P glycan, it could bind to the glycolipid
Gb4 (Figure 5). Given the differences in the ability of Stx1 and
Figure 7. Stx binding to Lyso-Gb3. Stx binding was assessed by
ELISA at 10 nM for both Stx1 (A) and Stx2 (B)a t3 7 uC. As negative
controls, toxin was incubated in methanol-coated wells. The RFU signal
is the mean of three independent experiments and error bars indicate
SD. Statistical differences were calculated by the two-tailed Student’s t-
test using GraphPad Prism
TM 5.
doi:10.1371/journal.pone.0030368.g007 Figure 8. Comparison of Stx binding to Gb3 in absence of
cholesterol or phosphatidylcholine. Stx binding was assessed by
ELISA at 10 nM for both Stx1 and Stx2 at 37uC as described in
Experimental Procedures. As negative controls, toxin was incubated in
methanol, PC, Ch or PC+Ch coated wells. In all experiments, RFU values
obtained in methanol were subtracted from each value in order to
define a base level. The RFU signal is the mean of three independent
experiments and error bars indicate SD. Statistical differences were
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the glycolipids Gb3 and Gb4 with nearly identical affinity when
PC and Ch are present (Figure 5).
Unlike Stx1, Stx2 binding to Gb3 is critically dependent on the
presence of other compounds, either another glycolipid such as
Gal-Cer or Ch (Figure 4). It is interesting to note that Stx2 but not
Stx1 is associated with neurologic damage, and Gal-Cer is highly
expressed on neuronal tissues [3,56]. The second component
could enhance binding of Stx2 to Gb3 either by directly contacting
the toxin or by inducing Gb3 to assume a conformation more
favorable for Stx2 binding. Ch has been shown to form hydrogen
bonds with the ceramide on glycolipids, leading to conformational
changes that make cells more susceptible to infection with HIV
[51,52,53]. We do not know if this mechanism is responsible for
increased binding of Stx2 in the presence of Ch. However, we do
not believe that the greatly improved binding of Stx2 to 1:1
mixture of Gb3 and Gal-Cer in the absence of Ch is achieved
through conformational changes, since the ceramide of Gal-Cer
and Gb3 is identical. An explanation that would account for the
increased binding of Stx2 in the presence of Ch and Gal-Cer is
that these molecules provide additional binding contacts. Stx2
could form hydrogen bonds with the galactose on Gal-Cer or with
cholesterol.
In addition to the potential for additional binding contacts, the
lower Hill coefficients observed for both Stx1 and Stx2 in the
presence of cholesterol suggest that different classes of avidity are
displayed on the plate surface, presumably due to heterogeneity in
the distribution of the molecules. Inclusion of PC and Ch may
favor formation of lipid microdomains that support Stx binding to
differing degrees, resulting in broadened binding curves due to
overlapping ranges of avidity depending on the localized geometry
of the glycans and how they interact with the binding sites on the
toxin. Clusters of glycolipids whose geometry precisely matches the
binding sites within the toxin would allow maximum apparent
affinity, and the reduced fluidity of the membrane upon addition
of Ch would increase the lifetime of such localized glycolipid
populations. This phenomenon may have important implications
for the in vivo biological activity of the toxin, since such broadened
binding curves exhibit detectable binding at very low toxin
concentrations.
Studies with chimeric toxins where the Stx1 and Stx2 A- and B-
subunits were reassorted demonstrated that potency tracks with
the B-subunit of Stx2 [15,17,26], strongly suggesting that potency
is determined by which cells are targeted, which is determined by
receptor usage. However, the current results do not explain the
difference in potency of Stx1 and Stx2. An enormous disparity
exists between the binding observed using biochemical assays
compared to cellular susceptibility. The Kd values of Stx1 and
Stx2 to Gb3 from this and previously published studies [15,23]
generally range between 10
27 M and 10
29 M. The concentration
of toxin in blood at 50% lethal dose in mice is approximately
10
29 M for Stx1 and 10
211 M for Stx2 [12]. However, both Stx1
and Stx2 are toxic to primary human renal proximal tubular
epithelial cells of the kidney with an ED50 of about 10
213 M [12]
and to the Vero monkey kidney cell line with an ED50 of about
10
211 M (Figure 10). Since we are unable to observe any binding
in vitro at these low doses, we examined the ability of toxin
preincubated with glycolipid to protect Vero cells from Stx-
mediated inhibition of protein synthesis. Even though nearly
identical Kds were observed for Stx1 and Stx2 binding to Gb3 and
Gb4 (Figure 4), Stx1 but not Stx2 was neutralized by prein-
cubation with Gb3 mixed with PC+CH (Figure 10). These studies
suggest that the in vitro glycolipid system replicates most of the
elements need for cellular binding of Stx1, but not Stx2.
Several properties of living cells could allow for toxin activity at
concentrations where no binding occurs in biochemical systems.
One major difference is the membranes of living cells are highly
Figure 9. Stx binding to Gb3 in presence of a cholesterol
analog. Stx binding was assessed by ELISA at 10 nM for both Stx1 (A)
and Stx2 (B) at 37uC. As negative controls, toxin was incubated in
methanol-coated wells. The RFU signal is the mean of three
independent experiments and error bars indicate SD. Statistical




Figure 10. Vero protection studies. Stx cellular toxicity was
assessed using luciferase activity of Luc2p Vero cells treated with
dilutions of Stx1 (A) or Stx2 (B) pre-incubated with glycolipid mixtures
as described in Figure 5. As negative controls, toxin was untreated or
incubated in methanol-coated wells or PC+Ch. The results are the
average of three independent experiments. Statistical difference
was calculated between untreated control and Gb3+PC+Ch treat-
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formed by membrane components bound to the rigid surface of
microtiter plates. Stx1 has been shown to induce tubular
membrane invaginations both in living cells and model mem-
branes [61], and the high concentration of Stx1 in the tubules
could drive toxin binding. Currently, there are no reports that
Stx2 can induce tubular invaginations.
In addition to membrane plasticity, living cells may express
other molecules which bind Stx1 or Stx2 with a higher affinity
than Gb3. In the glycan array (Figure 2), Stx1 bound better to
glycans containing GlcNAc at the third position instead of Glc
(Gala1-4Galb1-4GlcNAc versus Gala1-4Galb1-4Glc). In other
published reports [16,24], Stx2 preferred a Pk mimic (NAc-Pk:
NAcGala1-4Galb1-4Glc) to native Pk. While these preferred
glycans are not found on glycolipids, both are found on
glycoproteins, and accumulating reports suggest that Stx may
engage protein receptors. In 1999, Katagiri et al. were the first to
report that Stx induced activation of tyrosine kinase within
minutes of binding to a cell [57]. Recently, treatment with the B-
pentamer from either Stx1 or Stx2 was shown to promote release
of von Willebrand factor (VWF) from endothelial cells [58] by a
process that is dependent on Gb3 and cholesterol, and requires
caveolin-1, but not clathrin, and Stx2B can initiate activation of
the coagulation cascade in animal models of disease [59].
Furthermore, it has recently been shown that Stx1B and Stx2B
use different signaling pathways to promote VWF release [58]
Activation of VWF release by Stx1B is associated with transient
elevation of intracellular calcium, and requires both phospholipase
C and protein kinase C. In contrast, activation of VWF release by
Stx2B requires protein kinase A, which is activated in a cAMP-
independent manner. Stx could activate a signaling pathway by
binding to a protein receptor in a manner which mimics agonist
activation. Alternatively, Stx could promote receptor activation by
a lectin-like mechanism. Lectins activate signaling pathways that
respond to receptor-clustering. Like Stx, lectins possess multiple
glycan-binding sites, and can crosslink receptors via N- or O-
linked glycans present on receptor proteins. The presence of
protein receptors could enhance Stx bind to cells. However, it is
important to recognize that living cells can internalize the toxin,
and internalized toxin in a cellular system is equivalent to
irreversible binding in a biochemical system.
Important questions regarding the pathogenesis of Stx-mediated
disease remain unanswered. Why is Stx2 more likely to cause fatal
disease than Stx1? Why are children more susceptible than adults? Is
Stx-mediated killing of kidney epithelial cells more important than
Stx-mediated activation of the clotting cascade by kidney endothelial
cells? Since hemolytic uremic syndrome patients who also display
neurologic symptoms are more likely to succumb to fatal disease
[56,60], does Stx target the nervous system? Currently, only
supportive care is available for patients with Stx-mediated disease.
A detailed understanding of toxin binding preferences would allow us
to identify the cells, organ systems, and even individuals that are most
susceptible to the toxin. Such understanding is essential for the
development of effective treatment strategies.
Materials and Methods
Production of recombinant Stx toxoids and B-pentamers
Toxin-encoding genes were PCR amplified and cloned into the
expression plasmids, as outlined in Table 2 and 3. The sequence of
all inserts was verified. To generate the Stx2 toxoid expression
construct (pTSG218), the inactivated stx2 operon from pNR100
[40] was cloned as single PCR product. To generate the Stx1
toxoid expression construct, pTSG214 containing the stx1A and B
genes in tandem, tyrosine 77 and glutamic acid 167 of stx1A were
sequentially replaced with serine and glutamine, respectively using
the QuickChangeTM protocol (Stratagene) generating pTSG213.
stx1B was excised from pTSG211 with XbaI and NotI and cloned
into the NotI and SpeI site of pTSG213.
Proteins were expressed from cold-induced cultures as previ-
ously described [16,61], with the following modifications. Briefly,
logarithmic phase cultures were cooled to 8uC; expression of
recombinant toxoid and protein folding genes was induced by
addition of IPTG (0.1 mM) and ethanol (2%), respectively. After
overnight incubation with shaking at 20uC, the cells were
harvested by centrifugation, and lysed by gentle shaking with
4 M urea for 30 minutes. Cellular debris was removed by
centrifugation. The extract was dialyzed, and concentrated as a
40–70% ammonium sulfate fraction. Toxoids were further
purified using combinations of AffiGel Blue affinity chromatogra-
phy (Bio-Rad, CA), ion exchange, or size exclusion chromatog-
raphy. Pigeon egg white affinity chromatography [61] was used for
Stx1 toxoid. Protein was quantified using bicinchoninic acid
protein assay (Pierce, IL). Purity of toxoid was verified by the




pTSG210 Stx1A-WT pETSecS3 [41]/pMFUC-17 [26]
pTSG211 Stx1B-WT pETSecS3/pSW09 [40]
pTSG212 Stx1A-Y77S pTSG210 (This study)
pTSG213 Stx1A-Y77SE167Q pTSG212 (This study)
pTSG214 Stx1A-Y77SE167Q+Stx1B-WT pTSG213 (This study)
pTSG218 Stx2A-Y77SE167Q+Stx2B pETSecS3/pNR100 [40]
pTSG230 Stx2B-WT pETSecS3 [41]/pMFCU-21 [26]
doi:10.1371/journal.pone.0030368.t002
Table 3. Primers used in this study.
Cloning Primers
Name Sequence
59 Stx1A NdeI AACATATGATGAAAATAATTATTTTTAGAGTGC
39 Stx1A SpeI ATACTAGTTCAACTGCTAATAGTTCTGCGC
59 Stx1B NdeI AACATATGATGAAAAAAACATTATTAATAGCTGC
39 Stx1B SpeI ATACTAGTTCAACGAAAAATAACTTCGCTG
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on Coomassie stained 8–16% polyacrylamide gels (Lonza) loaded
with 1 mg of protein.
Isothermal Titration Calorimetry (ITC)
ITC experiments were performed in a Microcal VP-ITC
microcalorimeter at 25uC in buffer containing 20 mM HEPES at
pH 7.4 and 150 mM NaCl. Stx1B and Stx2B were dialyzed into
this buffer, and powdered Pk trisaccharide and P tetrasaccharide
glycans were resuspended in dialysate to achieve a buffer match.
All experiments were performed with Stx B-subunits in the
microcalorimeter cell at 238–300 mM concentration, and glycans
in the syringe at 50 mM concentration. The titrations consisted of
a total of forty 7-ml injections, spaced 120 seconds apart. Protein
concentrations were determined based on the UV absorbance at
280 nm and molar extinction coefficients of the Stx1B and Stx2B
monomers (8,605 M
21cm
21 and 14,105 M
21cm
21, respectively).
Data were analyzed in ORIGIN using a one-site binding model
with fixed n=1 per B subunit (the fixed parameter was required to
achieve convergence of the fit). The Kd values reported are the
average of two replicates.
Glycan array studies
Stx1 (2.84 mM) and Stx2 (0.64 mM) toxoids (obtained from the
BIODEFENSE AND EMERGING INFECTIOUS DISEASES RESEARCH RE-
SOURCES REPOSITORY, Manassas, VA) were submitted to the
Consortium for Functional Glycomics (CFG) to assess glycan binding
specificity. The Mammalian Printed Array Version 4.1 holds 465
different glycans consisting of natural and synthetic mammalian
glycans. Toxin binding was detected using rabbit polyclonal antibody
to Stx (Meridian Bioscience, Cincinnati, OH) and fluorescently
labeled anti-rabbit IgG Alexa 488 antibody which was supplied by
the CFG. The array consists of six replicates of each glycan, and
relative binding was expressed as mean relative fluorescence units
(RFU) of four of the six replicates after removal of the highest and
lowest values. Binding data can be accessed at the CFG website
(http://www.functionalglycomics.org/).
Glycolipid ELISA
Glycolipids and lipids (Table 1) were purchased from Matreya
Inc. (Pleasant Gap, PA). Pure glycolipids were suspended in
chloroform and diluted in methanol as previously described [31].
Mixtures of glycolipids were prepared in a molar ratio of 1:1.
Mixtures of glycolipids with cholesterol (Ch) and phosphatidyl-
choline (PC) were prepared in a molar ratio of 1:3:3 as previously
described [15]. Single or mixed glycolipids with or without Ch and
PC were added to wells of hydrophobic MicrotiterH plates
(MicrofluorH 1, Thermo scientific) and dried for 30 hours in a
fume hood. As negative controls, methanol alone, PC, Ch or
PC+Ch were added to wells. In all experiments, background RFU
values obtained in methanol were subtracted from each value.
Except were indicated, all steps were performed at 4uC. Prior to
use, the plates were blocked for 1 hour with phosphate buffered
saline (PBS; 8.1 mM Na2HPO4, 1.5 mM KH2PO4, 128 mM
NaCl, 2.7 mM KCl), pH 7.4, containing 2% (w/v) bovine serum
albumin (BSA). Dilutions of Stx toxoid were added and incubated
for 1 hour, followed by sequential incubation with primary
antibody against Stx1 or Stx2 (rabbit polyclonal serum, Meridian
Bioscience, Cincinnati, OH) and peroxidase-conjugated goat anti-
rabbit IgG (MP Biomedicals, Solon, OH). Wash steps were carried
out using cold PBS pH 7.4 containing 1% (w/v) BSA. Finally,
plates were developed with QuantaBluH fluorogenic peroxidase
substrate (Pierce, Rockford, IL) and read. Binding curves and
analysis were performed using Prism 5.0 (GraphPad Software, La
Jolla, CA).
Vero protection studies
Microtiter plates were coated with glycolipid as described
above. Wells treated with methanol alone, PC+Ch alone, or not
pre-treated served as negative controls. Unbound surfaces on the
wells were blocked with Minimal Essential Medium 16 (Invitro-
gen
TM) supplemented with 10% fetal bovine serum, vitamins
(Sigma-Aldrich
TM) and glutamine (Sigma
TM), and washed with PBS.
Stx1 and Stx2 (Biodefense and Emerging Infectious Diseases Research
Resources Repository, Manassas, VA) were serially diluted in PBS and
added to the wells, starting with 10
28 M of toxin. The toxin was
incubated at 37uC for 1 hour. After incubation, the toxin was
removed from the wells and added to tissue culture treated 96 well
plates (Corning Inc.
TM). The amount of residual toxin was
determined as previously described [12,62] by measuring protein
synthesis inhibition using Luc2P Vero cells engineered to express
destabilized luciferase [62] . Briefly, Luc2P Vero cells were added
at 10
4 cells per well. After 4 hours of incubation at 37uC and 5%
CO2, the cells were washed with PBS and 25 ml/well of SuperLight
luciferase substrate was added and luminescence was measured.
The results were reported as percentage of maximum signal from
PBS control cells incubated without any toxin. The effective dose
to inhibit 50% of protein synthesis (ED50) was calculated using the
two points above and below the midpoint and normalized against
the untreated control.
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